...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics

Bear,

"Since half patients are placebo and half are apabetalone, yes one should be able to double the apabetalone patient year estimate to obtain the total trial patient year estimate. With my revisions above, this BETonMACE total patient years would be 4960 to 5432 total BETonMACE patient years." (I added bolding)

Would a power of .80 (80%) to the above numbers apply here? 

 

Koo

Share
New Message
Please login to post a reply